-DOCSTART-	O

Title	O
:	O
Nano	B-I
-	I-I
curcumin	I-I
therapy	I-I
,	O
a	O
promising	O
method	O
in	O
modulating	O
inflammatory	O
cytokines	O
in	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
.	O

METHODS	O
:	O
Forty	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
and	I-P
40	I-P
healthy	I-P
controls	I-P
were	O
recruited	O
and	O
evaluated	O
for	O
inflammatory	O
cytokine	O
expression	O
and	O
secretion	O
.	O

Subsequently	O
,	O
COVID	O
-	O
19	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
20	O
patients	O
receiving	O
Nano	B-I
-	I-I
curcumin	I-I
and	O
20	O
patients	O
as	O
the	B-C
placebo	I-C
group	O
.	O

The	B-O
mRNA	I-O
expression	I-O
and	O
cytokine	B-O
secretion	I-O
levels	I-O
of	I-O
IL	I-O
-	I-O
1?	I-O
,	O
IL	B-O
-	I-O
6	I-O
,	O
TNF	B-O
-	I-O
?	I-O
and	O
IL	B-O
-	I-O
18	I-O
were	O
assessed	O
by	O
Real	B-O
-	I-O
time	I-O
PCR	I-O
and	O
ELISA	B-O
,	O
respectively	O
.	O

-DOCSTART-	O

Title	O
:	O
Homemade	B-I
valved	I-I
holding	I-I
chambers	I-I
for	O
children	B-P
with	I-P
airway	I-P
hyperresponsiveness	I-P
:	O
A	O
randomized	O
crossover	O
trial	O
.	O

METHODS	O
:	O
In	O
a	O
randomized	O
,	O
two	O
-	O
period	O
,	O
two	O
-	O
sequence	O
crossover	O
trial	O
,	O
we	O
recruited	O
20	B-P
children	I-P
,	I-P
aged	I-P
6	I-P
-	I-P
15	I-P
years	I-P
,	I-P
who	I-P
had	I-P
a	I-P
greater	I-P
than	I-P
12	I-P
%	I-P
increase	I-P
in	I-P
FEV1	I-P
after	I-P
inhaled	I-P
salbutamol	I-P
.	O

They	O
were	O
randomized	O
into	O
Group	O
A	O
and	O
B	O
.	O

Group	O
A	O
used	O
our	B-I
VHC	I-I
on	O
the	O
first	O
day	O
and	O
Aerochamber	B-I
on	O
the	O
second	O
day	O
.	O

Group	O
B	O
used	O
the	B-I
same	I-I
VHCs	I-I
but	O
in	O
alternate	O
sequence	O
.	O

Spirometries	B-O
were	O
performed	O
before	O
and	O
after	O
400	O
g	O
of	O
salbutamol	O
,	O
MDI	O
was	O
administered	O
via	O
those	B-I
VHCs	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
favipiravir	B-I
,	O
an	B-I
oral	I-I
RNA	I-I
-	I-I
dependent	I-I
RNA	I-I
polymerase	I-I
inhibitor	I-I
,	O
in	O
mild	O
-	O
to	O
-	O
moderate	O
COVID	O
-	O
19	O
:	O
A	O
randomized	O
,	O
comparative	O
,	O
open	O
-	O
label	O
,	O
multicenter	O
,	O
phase	O
3	O
clinical	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
arm	O
,	O
multicenter	O
,	O
phase	O
3	O
trial	O
,	O
adults	B-P
(	I-P
18	I-P
-	I-P
75	I-P
years	I-P
)	I-P
with	I-P
RT	I-P
-	I-P
PCR	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
symptoms	I-P
(	I-P
including	I-P
asymptomatic	I-P
)	I-P
were	O
randomized	O
1	O
:	O
1	O
to	O
oral	B-I
favipiravir	I-I
(	O
day	O
1	O
:	O
1800	O
mg	O
BID	O
and	O
days	O
2	O
-	O
14	O
:	O
800	O
mg	O
BID	O
)	O
plus	O
standard	B-I
supportive	I-I
care	I-I
versus	O
supportive	B-C
care	I-C
alone	I-C
.	O

The	O
primary	O
endpoint	O
was	O
time	B-O
to	I-O
the	I-O
cessation	I-O
of	I-O
viral	I-O
shedding	I-O
;	O
time	B-O
to	I-O
clinical	I-O
cure	I-O
was	O
also	O
measured	O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluating	O
the	O
effects	O
of	O
Intravenous	B-I
Immunoglobulin	I-I
(	I-I
IVIg	I-I
)	I-I
on	O
the	O
management	O
of	O
severe	O
COVID	O
-	O
19	O
cases	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
controlled	O
trial	O
,	O
84	B-P
patients	I-P
were	O
included	O
:	O
52	O
in	O
the	B-I
IVIg	I-I
group	O
and	O
32	O
in	O
the	O
control	O
group	O
.	O

The	O
intervention	O
group	O
received	O
IVIg	B-I
at	O
a	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
,	O
IV	O
,	O
daily	O
for	O
three	O
days	O
.	O

Both	O
groups	O
received	O
hydroxychloroquine	B-I
,	O
lopinavir	B-I
/	O
ritonavir	B-I
and	O
supportive	B-I
care	I-I
.	O

The	B-O
demographic	I-O
data	I-O
,	O
mortality	B-O
rate	I-O
,	O
the	B-O
need	I-O
for	I-O
mechanical	I-O
ventilation	I-O
,	O
length	B-O
of	I-O
stay	I-O
in	I-O
hospital	I-O
and	O
in	B-O
Intensive	I-O
Care	I-O
Unit	I-O
(	I-O
ICU	I-O
)	I-O
,	O
and	O
imaging	B-O
findings	I-O
were	O
recorded	O
and	O
compared	O
in	O
terms	O
of	O
the	O
mentioned	O
factors	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Randomized	O
Trial	O
of	O
Convalescent	B-I
Plasma	I-I
in	O
Covid	O
-	O
19	O
Severe	O
Pneumonia	O
.	O

METHODS	O
:	O
We	O
randomly	O
assigned	O
hospitalized	B-P
adult	I-P
patients	I-P
with	I-P
severe	I-P
Covid	I-P
-	I-P
19	I-P
pneumonia	I-P
in	O
a	O
2	O
:	O
1	O
ratio	O
to	O
receive	O
convalescent	B-I
plasma	I-I
or	O
placebo	B-C
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
patient	I-O
'	I-O
s	I-O
clinical	I-O
status	I-O
30	O
days	O
after	O
the	O
intervention	O
,	O
as	O
measured	O
on	O
a	B-O
six	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
ranging	O
from	O
total	O
recovery	O
to	O
death	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
hydroxychloroquine	B-I
and	O
a	O
retrospective	O
study	O
in	O
adult	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
coronavirus	I-P
disease	I-P
2019	I-P
(	I-P
COVID	I-P
-	I-P
19	I-P
)	I-P
.	O

METHODS	O
:	O
Subjects	B-P
admitted	I-P
to	I-P
11	I-P
designated	I-P
public	I-P
hospitals	I-P
in	I-P
Taiwan	I-P
between	I-P
April	I-P
1	I-P
and	I-P
May	I-P
31	I-P
,	I-P
2020	I-P
,	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
diagnosis	I-P
confirmed	I-P
by	I-P
pharyngeal	I-P
real	I-P
-	I-P
time	I-P
RT	I-P
-	I-P
PCR	I-P
for	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
,	O
were	O
randomized	O
at	O
a	O
2	O
:	O
1	O
ratio	O
and	O
stratified	O
by	O
mild	O
or	O
moderate	O
illness	O
.	O

HCQ	B-I
(	O
400	O
mg	O
twice	O
for	O
1	O
d	O
or	O
HCQ	B-I
200	O
mg	O
twice	O
daily	O
for	O
6	O
days	O
)	O
was	O
administered	O
.	O

Both	O
the	O
study	O
and	O
control	O
group	O
received	O
standard	B-C
of	I-C
care	I-C
(	I-C
SOC	I-C
)	I-C
.	O

Pharyngeal	O
swabs	O
and	O
sputum	O
were	O
collected	O
every	O
other	O
day	O
.	O

The	B-O
proportion	I-O
and	O
time	B-O
to	I-O
negative	I-O
viral	I-O
PCR	I-O
were	O
assessed	O
on	O
day	O
14	O
.	O

In	O
the	O
retrospective	O
study	O
,	O
medical	O
records	O
were	O
reviewed	O
for	O
patients	O
admitted	O
before	O
March	O
31	O
,	O
2020	O
.	O

-DOCSTART-	O

Title	O
:	O
Repurposed	O
Antiviral	O
Drugs	O
for	O
Covid	O
-	O
19	O
-	O
Interim	O
WHO	O
Solidarity	O
Trial	O
Results	O
.	O

METHODS	O
:	O
We	O
randomly	O
assigned	O
inpatients	B-P
with	I-P
Covid	I-P
-	I-P
19	I-P
equally	O
between	O
one	O
of	O
the	O
trial	O
drug	O
regimens	O
that	O
was	O
locally	O
available	O
and	O
open	O
control	O
(	O
up	O
to	O
five	O
options	O
,	O
four	B-I
active	I-I
and	O
the	B-C
local	I-C
standard	I-C
of	I-C
care	I-C
)	O
.	O

The	O
intention	O
-	O
to	O
-	O
treat	O
primary	O
analyses	O
examined	O
in	B-O
-	I-O
hospital	I-O
mortality	I-O
in	O
the	O
four	O
pairwise	O
comparisons	O
of	O
each	O
trial	O
drug	O
and	O
its	O
control	O
(	O
drug	O
available	O
but	O
patient	O
assigned	O
to	O
the	O
same	O
care	O
without	O
that	O
drug	O
)	O
.	O

Rate	B-O
ratios	I-O
for	I-O
death	I-O
were	O
calculated	O
with	O
stratification	O
according	O
to	O
age	O
and	O
status	O
regarding	O
mechanical	O
ventilation	O
at	O
trial	O
entry	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
propolis	B-I
supplementation	I-I
on	O
clinical	O
symptoms	O
in	O
patients	B-P
with	I-P
coronavirus	I-P
(	O
COVID	O
-	O
19	O
)	O
:	O
A	O
structured	O
summary	O
of	O
a	O
study	O
protocol	O
for	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
is	O
a	O
Double	O
-	O
Blind	O
,	O
Placebo	O
-	O
Controlled	O
,	O
Parallel	O
Arm	O
,	O
Randomized	O
Phase	O
??	O
Clinical	O
Trial	O
.	O

Patients	B-P
with	I-P
the	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
based	I-P
on	I-P
the	I-P
PCR	I-P
test	I-P
are	I-P
eligible	I-P
to	I-P
participate	I-P
in	I-P
the	I-P
trial	I-P
if	I-P
they	I-P
are	I-P
18	I-P
to	I-P
75	I-P
years	I-P
of	I-P
age	I-P
and	I-P
have	I-P
no	I-P
history	I-P
of	I-P
the	I-P
current	I-P
use	I-P
of	I-P
warfarin	I-P
or	I-P
propolis	I-P
supplement	I-P
and	I-P
presence	I-P
of	I-P
sensitivity	I-P
to	I-P
bee	I-P
products	I-P
.	O

Patients	O
will	O
be	O
recruited	O
from	O
the	O
Al	O
-	O
Zahra	O
hospital	O
in	O
Isfahan	O
city	O
,	O
Isfahan	O
,	O
Iran	O
.	O

METHODS	O
:	O
Eligible	O
patients	O
will	O
be	O
randomly	O
allocated	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
the	O
intervention	O
or	O
control	O
group	O
.	O

Randomization	O
will	O
be	O
performed	O
on	O
the	O
basis	O
of	O
permuted	O
block	O
sizes	O
of	O
4	O
and	O
will	O
be	O
stratified	O
according	O
to	O
sex	O
categories	O
.	O

Randomization	O
sequences	O
will	O
be	O
prepared	O
by	O
the	O
trial	O
'	O
s	O
pharmacist	O
with	O
the	O
use	O
of	O
random	O
-	O
number	O
tables	O
.	O

The	O
trial	O
-	O
group	O
assignment	O
will	O
be	O
concealed	O
from	O
all	O
participants	O
,	O
clinicians	O
,	O
and	O
investigators	O
throughout	O
the	O
trial	O
.	O

To	O
ensure	O
blinding	O
,	O
randomization	O
sequences	O
will	O
be	O
kept	O
in	O
identical	O
,	O
opaque	O
,	O
sealed	O
,	O
sequentially	O
numbered	O
envelopes	O
.	O

Only	O
the	O
trial	O
'	O
s	O
pharmacist	O
has	O
access	O
to	O
the	O
randomization	O
list	O
.	O

Also	O
,	O
the	O
placebo	O
tablet	O
will	O
be	O
similar	O
to	O
the	O
propolis	O
tablet	O
in	O
terms	O
of	O
texture	O
,	O
taste	O
,	O
color	O
,	O
odor	O
,	O
and	O
weight	O
.	O

Both	O
tablets	O
will	O
be	O
provided	O
in	O
containers	O
that	O
are	O
completely	O
identical	O
in	O
weight	O
,	O
shape	O
,	O
labelling	O
,	O
and	O
packaging	O
.	O

The	O
calculated	O
total	O
sample	O
size	O
is	O
80	O
patients	O
,	O
with	O
40	O
patients	O
in	O
each	O
group	O
.	O

The	O
protocol	O
is	O
Version	O
1	O
.	O
0	O
,	O
October	O
10	O
,	O
2020	O
.	O

Recruitment	O
began	O
August	O
22	O
,	O
2020	O
,	O
and	O
is	O
anticipated	O
to	O
be	O
completed	O
by	O
March	O
21	O
,	O
2021	O
.	O

METHODS	O
:	O
The	O
full	O
protocol	O
is	O
attached	O
as	O
an	O
additional	O
file	O
,	O
accessible	O
from	O
the	O
Trials	O
website	O
(	O
Additional	O
file	O
1	O
)	O
.	O

In	O
the	O
interest	O
of	O
expediting	O
the	O
dissemination	O
of	O
this	O
material	O
,	O
the	O
familiar	O
formatting	O
has	O
been	O
eliminated	O
;	O
this	O
Letter	O
serves	O
as	O
a	O
summary	O
of	O
the	O
key	O
elements	O
of	O
the	O
full	O
protocol	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Cluster	O
-	O
Randomized	O
Trial	O
of	O
Hydroxychloroquine	B-I
for	O
Prevention	O
of	O
Covid	O
-	O
19	O
.	O

METHODS	O
:	O
We	O
conducted	O
an	O
open	O
-	O
label	O
,	O
cluster	O
-	O
randomized	O
trial	O
involving	O
asymptomatic	B-P
contacts	I-P
of	I-P
patients	I-P
with	I-P
polymerase	I-P
-	I-P
chain	I-P
-	I-P
reaction	I-P
(	I-P
PCR	I-P
)	I-P
-	I-P
confirmed	I-P
Covid	I-P
-	I-P
19	I-P
in	I-P
Catalonia	I-P
,	I-P
Spain	I-P
.	O

We	O
randomly	O
assigned	O
clusters	O
of	O
contacts	O
to	O
the	B-I
hydroxychloroquine	I-I
group	O
(	O
which	O
received	O
the	O
drug	O
at	O
a	O
dose	O
of	O
800	O
mg	O
once	O
,	O
followed	O
by	O
400	O
mg	O
daily	O
for	O
6	O
days	O
)	O
or	O
to	O
the	B-C
usual	I-C
-	I-C
care	I-C
group	O
(	O
which	O
received	O
no	O
specific	O
therapy	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
PCR	B-O
-	I-O
confirmed	I-O
,	I-O
symptomatic	I-O
Covid	I-O
-	I-O
19	I-O
within	O
14	O
days	O
.	O

The	O
secondary	O
outcome	O
was	O
SARS	B-O
-	I-O
CoV	I-O
-	I-O
2	I-O
infection	I-O
,	O
defined	O
by	O
symptoms	B-O
compatible	I-O
with	I-O
Covid	I-O
-	I-O
19	I-O
or	O
a	B-O
positive	I-O
PCR	I-O
test	I-O
regardless	I-O
of	I-O
symptoms	I-O
.	O

Adverse	B-O
events	I-O
were	O
assessed	O
for	O
up	O
to	O
28	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
,	O
proof	O
-	O
of	O
-	O
concept	O
clinical	O
trial	O
of	O
modulation	O
of	O
host	O
thromboinflammatory	O
response	O
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
the	O
DAWn	O
-	O
Antico	O
study	O
.	O

METHODS	O
:	O
In	O
this	O
adaptive	O
,	O
open	O
-	O
label	O
multicenter	O
randomized	O
clinical	O
trial	O
,	O
we	O
compare	O
low	B-I
molecular	I-I
weight	I-I
heparins	I-I
at	O
50	O
IU	O
anti	O
-	O
Xa	O
/	O
kg	O
twice	O
daily	O
-	O
or	O
75	O
IU	O
anti	O
-	O
Xa	O
twice	O
daily	O
for	O
intensive	B-P
care	I-P
(	I-P
ICU	I-P
)	I-P
patients	I-P
-	O
in	O
combination	O
with	O
aprotinin	B-I
to	O
standard	B-I
thromboprophylaxis	I-I
in	O
hospitalized	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
.	O

In	O
the	O
case	O
of	O
hyperinflammation	O
,	O
the	O
interleukin	O
-	O
1	O
receptor	O
antagonist	O
anakinra	O
will	O
be	O
added	O
on	O
top	O
of	O
the	O
drugs	O
in	O
the	O
interventional	O
arm	O
.	O

In	O
a	O
pilot	O
phase	O
,	O
the	O
effect	O
of	O
the	O
intervention	O
on	O
thrombotic	B-O
markers	I-O
(	I-O
D	I-O
-	I-O
dimer	I-O
)	I-O
will	O
be	O
assessed	O
.	O

In	O
the	O
full	O
trial	O
,	O
the	O
primary	O
outcome	O
is	O
defined	O
as	O
the	O
effect	O
of	O
the	O
interventional	O
drugs	O
on	O
clinical	B-O
status	I-O
as	O
defined	O
by	O
the	B-O
WHO	I-O
ordinal	I-O
scale	I-O
for	I-O
clinical	I-O
improvement	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Baricitinib	B-I
plus	O
Remdesivir	B-I
for	O
Hospitalized	B-P
Adults	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
evaluating	O
baricitinib	B-I
plus	O
remdesivir	B-I
in	O
hospitalized	B-P
adults	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
.	O

All	O
the	O
patients	O
received	O
remdesivir	B-I
(	O
?10	O
days	O
)	O
and	O
either	O
baricitinib	B-I
(	O
?14	O
days	O
)	O
or	O
placebo	B-C
(	O
control	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
time	I-O
to	I-O
recovery	I-O
.	O

The	O
key	O
secondary	O
outcome	O
was	O
clinical	B-O
status	I-O
at	O
day	O
15	O
.	O

-DOCSTART-	O

Title	O
:	O
REGN	B-I
-	I-I
COV2	I-I
,	O
a	B-I
Neutralizing	I-I
Antibody	I-I
Cocktail	I-I
,	O
in	O
Outpatients	B-P
with	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
In	O
this	O
ongoing	O
,	O
double	O
-	O
blind	O
,	O
phase	O
1	O
-	O
3	O
trial	O
involving	O
nonhospitalized	B-P
patients	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
,	O
we	O
investigated	O
two	O
fully	O
human	O
,	O
neutralizing	O
monoclonal	O
antibodies	O
against	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
(	O
SARS	O
-	O
CoV	O
-	O
2	O
)	O
spike	O
protein	O
,	O
used	O
in	O
a	B-I
combined	I-I
cocktail	I-I
(	O
REGN	B-I
-	I-I
COV2	I-I
)	O
to	O
reduce	O
the	O
risk	O
of	O
the	O
emergence	O
of	O
treatment	O
-	O
resistant	O
mutant	O
virus	O
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
1:1:1	O
)	O
to	O
receive	O
placebo	B-C
,	O
2	B-I
.	I-I
4	I-I
g	I-I
of	I-I
REGN	I-I
-	I-I
COV2	I-I
,	O
or	O
8	B-I
.	I-I
0	I-I
g	I-I
of	I-I
REGN	I-I
-	I-I
COV2	I-I
and	O
were	O
prospectively	O
characterized	O
at	O
baseline	O
for	O
endogenous	O
immune	O
response	O
against	O
SARS	O
-	O
CoV	O
-	O
2	O
(	O
serum	O
antibody	O
-	O
positive	O
or	O
serum	O
antibody	O
-	O
negative	O
)	O
.	O

Key	O
end	O
points	O
included	O
the	O
time	O
-	O
weighted	O
average	O
change	O
in	O
viral	B-O
load	I-O
from	O
baseline	O
(	O
day	O
1	O
)	O
through	O
day	O
7	O
and	O
the	B-O
percentage	I-O
of	I-O
patients	I-O
with	I-O
at	I-O
least	I-O
one	I-O
Covid	I-O
-	I-O
19	I-O
-	I-O
related	I-O
medically	I-O
attended	I-O
visit	I-O
through	O
day	O
29	O
.	O

Safety	O
was	O
assessed	O
in	O
all	O
patients	O
.	O

-DOCSTART-	O

Title	O
:	O
Tocilizumab	B-I
in	O
Patients	B-P
Hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
Pneumonia	I-P
.	O

METHODS	O
:	O
We	O
randomly	O
assigned	O
(	O
in	O
a	O
2	O
:	O
1	O
ratio	O
)	O
patients	B-P
hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
pneumonia	I-P
who	I-P
were	I-P
not	I-P
receiving	I-P
mechanical	I-P
ventilation	I-P
to	O
receive	O
standard	B-I
care	I-I
plus	O
one	B-I
or	O
two	B-I
doses	I-I
of	I-I
either	I-I
tocilizumab	I-I
(	O
8	O
mg	O
per	O
kilogram	O
of	O
body	O
weight	O
intravenously	O
)	O
or	O
placebo	B-C
.	O

Site	O
selection	O
was	O
focused	O
on	O
the	O
inclusion	O
of	O
sites	O
enrolling	O
high	O
-	O
risk	O
and	O
minority	O
populations	O
.	O

The	O
primary	O
outcome	O
was	O
mechanical	B-O
ventilation	I-O
or	O
death	B-O
by	O
day	O
28	O
.	O

-DOCSTART-	O

Title	O
:	O
Sofosbuvir	B-I
and	O
daclatasvir	B-I
for	O
the	O
treatment	O
of	O
COVID	B-P
-	I-P
19	I-P
outpatients	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
in	O
outpatients	B-P
with	I-P
mild	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Patients	O
were	O
randomized	O
into	O
a	O
treatment	O
arm	O
receiving	O
sofosbuvir	B-I
/	O
daclatasvir	B-I
plus	O
hydroxychloroquine	B-I
or	O
a	O
control	O
arm	O
receiving	O
hydroxychloroquine	B-C
alone	I-C
.	O

The	O
primary	O
endpoint	O
of	O
the	O
trial	O
was	O
symptom	B-O
alleviation	I-O
after	O
7	O
days	O
of	O
follow	O
-	O
up	O
.	O

The	O
secondary	O
endpoint	O
of	O
the	O
trial	O
was	O
hospital	B-O
admission	I-O
.	O

Fatigue	B-O
,	O
dyspnoea	B-O
and	O
loss	B-O
of	I-O
appetite	I-O
were	O
investigated	O
after	O
1	O
month	O
of	O
follow	O
-	O
up	O
.	O

This	O
study	O
is	O
registered	O
with	O
the	O
IRCT	O
.	O
ir	O
under	O
registration	O
number	O
IRCT20200403046926N1	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Neutralizing	O
Monoclonal	O
Antibody	O
for	O
Hospitalized	B-P
Patients	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
In	O
this	O
platform	O
trial	O
of	O
therapeutic	O
agents	O
,	O
we	O
randomly	O
assigned	O
hospitalized	B-P
patients	I-P
who	I-P
had	I-P
Covid	I-P
-	I-P
19	I-P
without	I-P
end	I-P
-	I-P
organ	I-P
failure	I-P
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
either	O
LY	B-I
-	I-I
CoV555	I-I
or	O
matching	B-C
placebo	I-C
.	O

In	O
addition	O
,	O
all	O
the	O
patients	O
received	O
high	O
-	O
quality	O
supportive	O
care	O
as	O
background	O
therapy	O
,	O
including	O
the	B-I
antiviral	I-I
drug	I-I
remdesivir	I-I
and	O
,	O
when	O
indicated	O
,	O
supplemental	B-I
oxygen	I-I
and	O
glucocorticoids	B-I
.	O

LY	B-I
-	I-I
CoV555	I-I
(	O
at	O
a	O
dose	O
of	O
7000	O
mg	O
)	O
or	O
placebo	B-C
was	O
administered	O
as	O
a	O
single	O
intravenous	O
infusion	O
over	O
a	O
1	O
-	O
hour	O
period	O
.	O

The	O
primary	O
outcome	O
was	O
a	B-O
sustained	I-O
recovery	I-O
during	O
a	O
90	O
-	O
day	O
period	O
,	O
as	O
assessed	O
in	O
a	O
time	O
-	O
to	O
-	O
event	O
analysis	O
.	O

An	O
interim	O
futility	O
assessment	O
was	O
performed	O
on	O
the	O
basis	O
of	O
a	O
seven	B-O
-	I-O
category	I-O
ordinal	I-O
scale	I-O
for	I-O
pulmonary	I-O
function	I-O
on	O
day	O
5	O
.	O

